Matratzenträger zur Auflagerung der Matratze eines Bettes, dadurch gekennzeichnet, dass dieser parallele Schichten aufweist, von denen die oberste und die unterste Schicht aus Kork bestehen und eine dazwischen liegende Schicht der Tragfähigkeit und Aussteifung des Trägers dient.

Disclosed is an extracorporeal filtration and detoxification system and method generally comprising: (a) separating ultrafiltrate fluid from cellular components of blood that has been drawn from a patient; (b) treating said ultrafiltrate independently of said cellular components in a recirculation circuit, wherein said treating comprises circulating said ultrafiltrate through an active cartridge c...

Provided is a process of producing a pharmaceutical composition comprising crystalline suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: (a) blending 60-5% of a first batch of crystalline suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof having a mean particle size of less than 60 micrometers an...

Disclosed are cyclohexyl-urea derivatives as represented by the general formula: R1-P1-L1-P2-L2-(P3)m; wherein R1 represents a substituted or unsubstituted adamantyl, cyclohexyl or phenyl group; P1 is NHC(O)NH-; L1 is a substituted or unsubstituted cyclohexylene group; L2 is a linker as defined herein; P2 is a secondary pharmacophore selected from the group consisting of -NH-, -C(O)-, -CH(OH)-, -O...

Disclosed is an additive when used to reduces Cr(VI) ions to Cr(III) ions, comprising an aqueous solution of a complex of tin(II), and a carboxylic acid such as gluconic acid or a salt thereof, wherein the additive has a pH over 2. Also disclosed is the use of the additive for preparing a material such as a cement, fly ash or slag with reduced chromium (VI) content; and a process for preparing the...

Disclosed is a stable liquid composition comprising a chelating agent, histidine and at least one human IgG2 antibody that bind to CTLA-4. The composition has at least one property that is improved compared to an otherwise identical composition lacking the chelating agent, selected from the group consisting of: a) Reduced aggregation of the antibody; b) Reduced fragmentation of the antibody; c) Re...

Disclosed is a dual specificity oligonucleotide with enhanced annealing specificity, which is represented by the following general formula 5'-Xp-Yq-Zr-3' wherein the substituents are as defined in the specification. Methods for synthesizing a nucleic acid using the dual specificity oligonucleotide are also disclosed.

Disclosed is a retortable multilayer packaging film comprising: (A) a crosslinked heat seal layer comprising a C2-3/C3-20 alpha-olefin copolymer, the heat seal layer being an outer layer; (B) a crosslinked grease-resistant layer comprising a crystalline anhydride-grafted C2-3/C6-20 alpha-olefin copolymer having a density of from 0.93 g/cc to 0.97 g/cc, and optionally at least one member selected f...

Disclosed here are specific 7-aminio alkyidenyl-heterocyclic quinolones and naphthyridones as generally represented by the structure of formula I, wherein A is C or N, R3 is F or H, processes for their preparation and compositions comprising said compounds. Such compounds are useful in the treatment/prevention of conditions caused by or contributed to by bacterial infection.

Disclosed is the use of a compound selected from the group consisting of Roflumilast,(also known as 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-difluoromethoxy)benzamide) a pharmaceutically acceptable salt of Roflumilast, Roflumilast-N-Oxide and a pharmaceutically acceptable salt of Roflumilast-N-Oxide in combination with SILDENAFIL (also known as 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-ox...

Disclosed is an in situ conversion system for producing hydrocarbons from a subsurface formation (232). The system comprises a plurality of u-shaped wellbores in the formation; piping (220) positioned in at least two of the u-shaped well bores; a fluid system (222) coupled to the piping; and an electrical power supply. The power supply provides electrical current to at least a portion of the pipin...

A computer system for accelerated animation using point multiplication and soft caching includes a memory configured to store a set of training data for an animation variable and a processor coupled to the memory. The processor is configured to determine an animation variable response subspace within an animation variable response space, in response to a set of training data for the animation vari...

A method for inactivating pathogens and/or leucocytes in platelet concentrates (PCs). The method comprises the steps: (1) Providing PCs obtained from donor blood or by mechanical apheresis; (2) Exposing the PCs to irradiation with ultraviolet C (UVC) light between 200-280 nm The PC is placed in a flexible, UV-penetrable flat exposure bag and filled to less than 30% of the maximum filling volume of...

The disclosure is directed to dibenzene derivative compounds of formula (I) having voltage-dependant calcium channel (VDCC) blocking activity, wherein the variables are as defined in the specification. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions selected from stroke, ischemia, anxiety, e...

Disclosed is an isolated IL-23p19 antibody. Also disclosed is the use of the antibody in the manufacture of a medicament for diagnosing or treating an IL-23 related condition selected from psoriasis, psoriatic arthritis, Crohn's disease, multiple sclerosis and optic neuritis.

Disclosed herein are the use of aminoisoindoline compounds of (+)-2-[I-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-I,3-dione, or a pharmaceutically acceptable salt or solvate thereof: substantially free of its (-) enantiomer; 4-(amino)-2-(2,6- dioxo(3-piperidyl))-isoindoline-I,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof; 3-(4-amino...

Disclosed is the use of (i) the compound ((2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)-L-valinyl)5 amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane) (ritonavir) or a pharmaceutically acceptable salt, and (ii) an HIV integrase inhibitor, in the manufacture of a medicament for improving the pharmacokinetics of an HIV integrase inhibit...

Disclosed is a dichloronathtelene and quinoline compounds having a structure of Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt or solvate thereof: wherein n is an integer selected from 0 to 2; D is CX-Ar1 or N-Ar1; m is 1; each X is independently H or OH; Ar1 is defined in the specification V and W are independently selected from H or OR9 ; wherein...

Disclosed is a cycloalkane amine having a structure according to Formula (I) or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemic mixture, enantiomerically enriched mixture, or enantiomerically pure form thereof, wherein n is 0 or 1; s is 1,2, or 3; m is an integer from 0 to 12 and Ar, X, R1, R2, R3 and R4 are as defined in the specification. Also disclosed is the use ...

Disclosed herein is a compound 2-[6-(methylamino)pyridine-3-yl]-1,3-benzothiazol-6-ol wherein one or more of the atoms are optionally a detectable isotope; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof. Also disclosed is { N-methyl-11C]-2-(6-(methylamino)pyridine-3-yl]-benzothiazole-6-ol. Use of said compounds in the manufacture of a medicament for meas...